Genmab A/S announced that daratumumab will be investigated in Phase Ib/II clinical studies in combination with nivolumab (a PD-1 checkpoint inhibitor) in several solid tumor types and in multiple myeloma. The studies will be conducted under a clinical trial collaboration agreement between Genmab's licensing partner for daratumumab, Janssen Biotech Inc., and Bristol-Myers Squibb (BMS). The studies will be sponsored by BMS. The solid tumor studies will evaluate the safety, tolerability and clinical benefit of daratumumab in combination with nivolumab in patients with advanced or metastatic tumors including non-small cell lung, head and neck, pancreatic, colorectal and triple negative breast cancers. Additional tumor types may also be evaluated. The multiple myeloma study will evaluate the safety and tolerability of daratumumab in combination with nivolumab with or without pomalidomide and dexamethasone in relapsed-refractory multiple myeloma. Studies are expected to start in 2017.